COST-EFFECTIVENESS ANALYSIS OF AROMATASE INHIBITORS AND TAMOXIFEN AS AN ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY-STAGE HORMONE RECEPTOR POSITIVE BREAST CANCER

被引：0
|
作者：
Sura, S. D. [1 ]
Sansgiry, S. S. [1 ]
机构：
[1] Univ Houston, Houston, TX USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.1186
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A220 / A220
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
    Delea, Thomas E.
    Karnon, Jon
    Sofrygin, Oleg
    Thomas, Simu K.
    Papo, Natalie L.
    Barghout, Victoria
    [J]. CLINICAL BREAST CANCER, 2007, 7 (08) : 608 - 618
  • [2] Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
    Butani, Dimple
    Gupta, Nidhi
    Jyani, Gaurav
    Bahuguna, Pankaj
    Kapoor, Rakesh
    Prinja, Shankar
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2021, 13 : 625 - 640
  • [3] A cost-effectiveness analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with early-stage breast cancer in Mexico
    Mould-Quevedo, J.
    Tapia-Valencia, J.
    Davila-Loaiza, G.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A124 - A125
  • [4] Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer in the UK
    Karnon, J
    Delea, TE
    Papo, NL
    Barghout, V
    Thomas, SK
    Johnston, SR
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A43 - A43
  • [5] Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
    Delea, Thomas E.
    Karnon, Jonathan
    Smith, Robert E.
    Johnston, Stephen R. D.
    Brandman, Jane
    Sung, Jennifer C. Y.
    Goss, Paul E.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2006, 12 (07): : 374 - 386
  • [6] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer.
    Delea, T. E.
    Karnon, J.
    Sofrygin, O.
    Thomas, S. K.
    Barghout, V
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S116 - S117
  • [7] Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the UK perspective
    Karnon, J
    Delea, TE
    Barghout, V
    Thomas, SK
    Papo, NL
    Johnston, SRD
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S104 - S104
  • [8] Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer:: the Belgian perspective
    Kannon, J.
    Berliere, M.
    Depypere, H.
    Dirix, L.
    Jerusalem, G.
    Neven, P.
    Pandaens, R.
    Lecomte, P.
    [J]. BREAST, 2007, 16 : S64 - S65
  • [9] Comparison of cost-effectiveness of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
    El Ouagari, K.
    Kamon, J.
    Kaura, S.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 210 - 211
  • [10] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    Delea, Thomas E.
    El-Ouagari, Khalid
    Karnon, Jonathan
    Sofrygin, Oleg
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (03) : 375 - 387
12345